Pacific Biosciences of California, Inc.
Index- P/E- EPS (ttm)-0.92 Insider Own0.80% Shs Outstand224.50M Perf Week10.15%
Market Cap1.26B Forward P/E- EPS next Y-1.34 Insider Trans-5.18% Shs Float205.10M Perf Month-0.94%
Income-205.70M PEG- EPS next Q-0.34 Inst Own97.50% Short Float14.78% Perf Quarter29.87%
Sales139.50M P/S9.03 EPS this Y-628.30% Inst Trans2.59% Short Ratio3.86 Perf Half Y-36.21%
Book/sh3.04 P/B1.91 EPS next Y2.20% ROA-10.50% Target Price10.00 Perf Year-77.28%
Cash/sh4.15 P/C1.40 EPS next 5Y-1.00% ROE-27.00% 52W Range3.85 - 31.10 Perf YTD-71.63%
Dividend- P/FCF- EPS past 5Y-1.30% ROI-10.00% 52W High-81.33% Beta1.30
Dividend %- Quick Ratio11.10 Sales past 5Y7.50% Gross Margin44.80% 52W Low50.78% ATR0.62
Employees728 Current Ratio11.50 Sales Q/Q16.00% Oper. Margin- RSI (14)49.33 Volatility11.76% 10.74%
OptionableYes Debt/Eq1.31 EPS Q/Q-54.00% Profit Margin- Rel Volume0.61 Prev Close5.60
ShortableYes LT Debt/Eq1.31 EarningsAug 03 AMC Payout- Avg Volume7.86M Price5.80
Recom2.30 SMA20-1.10% SMA50-2.90% SMA200-32.57% Volume4,883,830 Change3.66%
Jan-21-22Resumed Cantor Fitzgerald Overweight $62 → $31
Jan-06-22Resumed Piper Sandler Neutral $20
Oct-15-21Resumed Cowen Market Perform $30
Sep-27-21Initiated Canaccord Genuity Buy $45
Feb-11-21Upgrade Piper Sandler Neutral → Overweight $20 → $52
Nov-03-20Downgrade Piper Sandler Overweight → Neutral $12
Oct-02-20Upgrade JP Morgan Neutral → Overweight $15
Sep-09-20Initiated Morgan Stanley Equal-Weight $7
Jun-02-20Resumed Cantor Fitzgerald Overweight $5
Mar-09-20Resumed Cantor Fitzgerald Overweight $5
Oct-15-19Upgrade Piper Jaffray Neutral → Overweight $8
Apr-02-19Downgrade Stephens Overweight → Equal-Weight $4.50 → $8
Oct-19-18Initiated Cowen Outperform
Nov-03-17Downgrade First Analysis Sec Overweight → Equal-Weight $4
Sep-28-17Downgrade CL King Buy → Neutral
Nov-03-16Reiterated Cantor Fitzgerald Buy $18 → $15
Jun-27-16Initiated CL King Buy
Apr-15-16Initiated First Analysis Sec Overweight $11
Feb-04-16Downgrade Piper Jaffray Overweight → Neutral
Jan-04-16Reiterated Cantor Fitzgerald Buy $11 → $18
Sep-28-22 01:08PM
Sep-27-22 09:05AM
Sep-21-22 08:02AM
Sep-07-22 04:05PM
Aug-19-22 04:05PM
06:12AM Loading…
Aug-08-22 06:12AM
Aug-05-22 09:00AM
Aug-04-22 12:30PM
Aug-03-22 05:45PM
Aug-01-22 02:26AM
Jul-21-22 09:15AM
04:03PM Loading…
Jul-18-22 04:03PM
Jun-27-22 08:00PM
Jun-14-22 09:00AM
Jun-06-22 08:44AM
May-25-22 03:00PM
May-24-22 05:10PM
May-08-22 07:00PM
May-05-22 04:10PM
May-04-22 06:05PM
Apr-27-22 03:03PM
Apr-21-22 09:16AM
09:00AM Loading…
Apr-20-22 04:02PM
Apr-12-22 08:25AM
Apr-04-22 09:00AM
Mar-31-22 02:00PM
Mar-23-22 09:00AM
Mar-18-22 11:00AM
Mar-17-22 11:30AM
Mar-07-22 10:57AM
Feb-28-22 09:00AM
Feb-25-22 05:00PM
Feb-23-22 09:54AM
Feb-16-22 09:53AM
Feb-15-22 05:55PM
Feb-09-22 04:05PM
Feb-08-22 08:53AM
Feb-02-22 03:01PM
Feb-01-22 04:05PM
Jan-18-22 08:56AM
Jan-17-22 09:16AM
Jan-14-22 04:05PM
Jan-13-22 07:00AM
Jan-12-22 09:35AM
Jan-11-22 01:13PM
Jan-10-22 10:17AM
Jan-07-22 09:00AM
Jan-06-22 11:58AM
Jan-05-22 09:00AM
Jan-04-22 04:05PM
Dec-29-21 11:05AM
Dec-28-21 09:00AM
Dec-17-21 09:04AM
Dec-12-21 10:49PM
Dec-10-21 08:20AM
Dec-09-21 12:32PM
Dec-07-21 09:00AM
Dec-03-21 05:00PM
Nov-30-21 09:00AM
Nov-26-21 03:58PM
Nov-22-21 05:37PM
Nov-19-21 05:00PM
Nov-18-21 10:29AM
Nov-16-21 09:00AM
Nov-11-21 04:05PM
Nov-03-21 08:00PM
Nov-02-21 05:55PM
Oct-27-21 06:17AM
Oct-26-21 03:02PM
Oct-19-21 04:05PM
Oct-18-21 09:02AM
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HENRY CHRISTIAN OSee RemarksSep 15Sale5.7891,307527,435688,551Sep 19 07:17 PM
MOHR MARSHALLDirectorJun 10Option Exercise1.8335,00064,05060,000Jun 13 08:36 PM
Farmer MicheleSee RemarksMay 18Sale5.553,57319,81960,354May 20 03:31 PM
Kim Susan G.Chief Financial OfficerFeb 17Sale11.061,06211,746134,966Feb 22 04:47 PM
HENRY CHRISTIAN OPresident & CEOFeb 17Sale11.092,12223,533672,358Feb 22 04:44 PM
ORDONEZ KATHYDirectorFeb 16Sale11.503,28037,72018,595Feb 17 08:11 PM
MOHR MARSHALLDirectorJan 14Option Exercise3.5725,00089,25025,000Jan 19 06:54 PM
Van Oene MarkChief Operating OfficerJan 11Sale14.2341,480590,260293,520Jan 13 06:15 PM
Fromen PeterChief Commercial OfficerJan 11Sale14.3019,720281,996140,280Jan 13 06:13 PM